Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 27 entries
Sorted by: Best Match Show Resources per page
Patents and literature.

Applied biochemistry and biotechnology

Kit M, Narasimhan MJ, Anderson JA, Zimmermann U, Pilwat G, Furuya T, Tani Y, Kolehmainen SE, Tarkkanen V, Barrett SP, Gestrelius SM, Belloc A, Florent J, Lunel J, Palla J, Mancy D, Bailey JE, Cho YK, Mouri T, Kayama H, Foley SE, Oriel PJ, Epstein CC, Kimura K, Spraker PW, Ljungdahl LG, Wieget JK, Levine DW, Thilly WG, Wang DI, Wong JS, Eisinger MG, Young FE, Wilson GA, Mottice SL, Green H, Kehinde O, Buhler M, Olofsson M, Osseux PF, Degen L, Branduzzi P, Olivieri R, Cimini N, Kang KS, Veeder GT, Latymer Z, Andersen G, Drobot W, Monsheimer R, Pfleiderer E, Hidaka H, Kohno T, Eida T, Weisrock WP, Stevens VC, Takezawa K, Hiratani H, Wandrey C, Wichmann R, Leuchtenberger W, Kula M, Buckmann A, Troller J, Koshugi J, Frommer W, Muller L, Schmidt D, Puls W, Krause H, Heber U, Cohen SN, Wahl GM, Stark GR, Collins J, Hohn B, Sugano H, Matsui Y.
PMID: 24234232
Appl Biochem Biotechnol. 1982 May;7(3):217-30. doi: 10.1007/BF02798299.

No abstract available.

Cite
Kit M, Narasimhan MJ, Anderson JA, et al. Patents and literature. Appl Biochem Biotechnol. 1982;7(3):217-30doi: 10.1007/BF02798299.
Kit, M., Narasimhan, M. J., Anderson, J. A., Zimmermann, U., Pilwat, G., Furuya, T., Tani, Y., Kolehmainen, S. E., Tarkkanen, V., Barrett, S. P., Gestrelius, S. M., Belloc, A., Florent, J., Lunel, J., Palla, J., Mancy, D., Bailey, J. E., Cho, Y. K., Mouri, T., Kayama, H., Foley, S. E., Oriel, P. J., Epstein, C. C., Kimura, K., Spraker, P. W., Ljungdahl, L. G., Wieget, J. K., Levine, D. W., Thilly, W. G., Wang, D. I., Wong, J. S., Eisinger, M. G., Young, F. E., Wilson, G. A., Mottice, S. L., Green, H., Kehinde, O., Buhler, M., Olofsson, M., Osseux, P. F., Degen, L., Branduzzi, P., Olivieri, R., Cimini, N., Kang, K. S., Veeder, G. T., Latymer, Z., Andersen, G., Drobot, W., Monsheimer, R., Pfleiderer, E., Hidaka, H., Kohno, T., Eida, T., Weisrock, W. P., Stevens, V. C., Takezawa, K., Hiratani, H., Wandrey, C., Wichmann, R., Leuchtenberger, W., Kula, M., Buckmann, A., Troller, J., Koshugi, J., Frommer, W., Muller, L., Schmidt, D., Puls, W., Krause, H., Heber, U., Cohen, S. N., Wahl, G. M., Stark, G. R., Collins, J., Hohn, B., Sugano, H., & Matsui, Y. (1982). Patents and literature. Applied biochemistry and biotechnology, 7(3), 217-30. https://doi.org/10.1007/BF02798299
Kit, M, et al. "Patents and literature." Applied biochemistry and biotechnology vol. 7,3 (1982): 217-30. doi: https://doi.org/10.1007/BF02798299
Kit M, Narasimhan MJ, Anderson JA, Zimmermann U, Pilwat G, Furuya T, Tani Y, Kolehmainen SE, Tarkkanen V, Barrett SP, Gestrelius SM, Belloc A, Florent J, Lunel J, Palla J, Mancy D, Bailey JE, Cho YK, Mouri T, Kayama H, Foley SE, Oriel PJ, Epstein CC, Kimura K, Spraker PW, Ljungdahl LG, Wieget JK, Levine DW, Thilly WG, Wang DI, Wong JS, Eisinger MG, Young FE, Wilson GA, Mottice SL, Green H, Kehinde O, Buhler M, Olofsson M, Osseux PF, Degen L, Branduzzi P, Olivieri R, Cimini N, Kang KS, Veeder GT, Latymer Z, Andersen G, Drobot W, Monsheimer R, Pfleiderer E, Hidaka H, Kohno T, Eida T, Weisrock WP, Stevens VC, Takezawa K, Hiratani H, Wandrey C, Wichmann R, Leuchtenberger W, Kula M, Buckmann A, Troller J, Koshugi J, Frommer W, Muller L, Schmidt D, Puls W, Krause H, Heber U, Cohen SN, Wahl GM, Stark GR, Collins J, Hohn B, Sugano H, Matsui Y. Patents and literature. Appl Biochem Biotechnol. 1982 May;7(3):217-30. doi: 10.1007/BF02798299. PMID: 24234232.
Copy Download .nbib Format: NLM
The treatment of spontaneous breast adenocarci-nomas in mice with extracts of spleen or yeast.

The American journal of pathology

Lewisohn R, Leuchtenberger C, Leuchtenberger R, Laszlo D.
PMID: 19970557
Am J Pathol. 1941 Mar;17(2):251-260.5.

No abstract available.

Cite
Lewisohn R, Leuchtenberger C, Leuchtenberger R, et al. The treatment of spontaneous breast adenocarci-nomas in mice with extracts of spleen or yeast. Am J Pathol. 1941;17(2):251-260.5
Lewisohn, R., Leuchtenberger, C., Leuchtenberger, R., & Laszlo, D. (1941). The treatment of spontaneous breast adenocarci-nomas in mice with extracts of spleen or yeast. The American journal of pathology, 17(2), 251-260.5.
Lewisohn, R, et al. "The treatment of spontaneous breast adenocarci-nomas in mice with extracts of spleen or yeast." The American journal of pathology vol. 17,2 (1941): 251-260.5.
Lewisohn R, Leuchtenberger C, Leuchtenberger R, Laszlo D. The treatment of spontaneous breast adenocarci-nomas in mice with extracts of spleen or yeast. Am J Pathol. 1941 Mar;17(2):251-260.5. PMID: 19970557; PMCID: PMC1965186.
Copy Download .nbib Format: NLM
INOSITOL A TUMOR GROWTH INHIBITOR.

Science (New York, N.Y.)

Laszlo D, Leuchtenberger C.
PMID: 17777475
Science. 1943 Jun 04;97(2527):515. doi: 10.1126/science.97.2527.515.

No abstract available.

Cite
Laszlo D, Leuchtenberger C. INOSITOL A TUMOR GROWTH INHIBITOR. Science. 1943;97(2527):515doi: 10.1126/science.97.2527.515.
Laszlo, D., & Leuchtenberger, C. (1943). INOSITOL A TUMOR GROWTH INHIBITOR. Science (New York, N.Y.), 97(2527), 515. https://doi.org/10.1126/science.97.2527.515
Laszlo, D, and Leuchtenberger, C. "INOSITOL A TUMOR GROWTH INHIBITOR." Science (New York, N.Y.) vol. 97,2527 (1943): 515. doi: https://doi.org/10.1126/science.97.2527.515
Laszlo D, Leuchtenberger C. INOSITOL A TUMOR GROWTH INHIBITOR. Science. 1943 Jun 04;97(2527):515. doi: 10.1126/science.97.2527.515. PMID: 17777475.
Copy Download .nbib Format: NLM
Characterising a homozygous two-exon deletion in UQCRH: comparing human and mouse phenotypes.

EMBO molecular medicine

Vidali S, Gerlini R, Thompson K, Urquhart JE, Meisterknecht J, Aguilar-Pimentel JA, Amarie OV, Becker L, Breen C, Calzada-Wack J, Chhabra NF, Cho YL, da Silva-Buttkus P, Feichtinger RG, Gampe K, Garrett L, Hoefig KP, Hölter SM, Jameson E, Klein-Rodewald T, Leuchtenberger S, Marschall S, Mayer-Kuckuk P, Miller G, Oestereicher MA, Pfannes K, Rathkolb B, Rozman J, Sanders C, Spielmann N, Stoeger C, Szibor M, Treise I, Walter JH, Wurst W, Mayr JA, Fuchs H, Gärtner U, Wittig I, Taylor RW, Newman WG, Prokisch H, Gailus-Durner V, Hrabě de Angelis M.
PMID: 34750991
EMBO Mol Med. 2021 Dec 07;13(12):e14397. doi: 10.15252/emmm.202114397. Epub 2021 Nov 08.

Mitochondrial disorders are clinically and genetically diverse, with isolated complex III (CIII) deficiency being relatively rare. Here, we describe two affected cousins, presenting with recurrent episodes of severe lactic acidosis, hyperammonaemia, hypoglycaemia and encephalopathy. Genetic investigations in both cases...

Cite
Vidali S, Gerlini R, Thompson K, et al. Characterising a homozygous two-exon deletion in UQCRH: comparing human and mouse phenotypes. EMBO Mol Med. 2021;13(12):e14397doi: 10.15252/emmm.202114397.
Vidali, S., Gerlini, R., Thompson, K., Urquhart, J. E., Meisterknecht, J., Aguilar-Pimentel, J. A., Amarie, O. V., Becker, L., Breen, C., Calzada-Wack, J., Chhabra, N. F., Cho, Y. L., da Silva-Buttkus, P., Feichtinger, R. G., Gampe, K., Garrett, L., Hoefig, K. P., Hölter, S. M., Jameson, E., Klein-Rodewald, T., Leuchtenberger, S., Marschall, S., Mayer-Kuckuk, P., Miller, G., Oestereicher, M. A., Pfannes, K., Rathkolb, B., Rozman, J., Sanders, C., Spielmann, N., Stoeger, C., Szibor, M., Treise, I., Walter, J. H., Wurst, W., Mayr, J. A., Fuchs, H., Gärtner, U., Wittig, I., Taylor, R. W., Newman, W. G., Prokisch, H., Gailus-Durner, V., & Hrabě de Angelis, M. (2021). Characterising a homozygous two-exon deletion in UQCRH: comparing human and mouse phenotypes. EMBO molecular medicine, 13(12), e14397. https://doi.org/10.15252/emmm.202114397
Vidali, Silvia, et al. "Characterising a homozygous two-exon deletion in UQCRH: comparing human and mouse phenotypes." EMBO molecular medicine vol. 13,12 (2021): e14397. doi: https://doi.org/10.15252/emmm.202114397
Vidali S, Gerlini R, Thompson K, Urquhart JE, Meisterknecht J, Aguilar-Pimentel JA, Amarie OV, Becker L, Breen C, Calzada-Wack J, Chhabra NF, Cho YL, da Silva-Buttkus P, Feichtinger RG, Gampe K, Garrett L, Hoefig KP, Hölter SM, Jameson E, Klein-Rodewald T, Leuchtenberger S, Marschall S, Mayer-Kuckuk P, Miller G, Oestereicher MA, Pfannes K, Rathkolb B, Rozman J, Sanders C, Spielmann N, Stoeger C, Szibor M, Treise I, Walter JH, Wurst W, Mayr JA, Fuchs H, Gärtner U, Wittig I, Taylor RW, Newman WG, Prokisch H, Gailus-Durner V, Hrabě de Angelis M. Characterising a homozygous two-exon deletion in UQCRH: comparing human and mouse phenotypes. EMBO Mol Med. 2021 Dec 07;13(12):e14397. doi: 10.15252/emmm.202114397. Epub 2021 Nov 08. PMID: 34750991; PMCID: PMC8649870.
Copy Download .nbib Format: NLM
Hypoxia-Inducible Factor 1 Alpha-Mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence.

Hepatology (Baltimore, Md.)

Riedl T, Faure-Dupuy S, Rolland M, Schuehle S, Hizir Z, Calderazzo S, Zhuang X, Wettengel J, Lopez MA, Barnault R, Mirakaj V, Prokosch S, Heide D, Leuchtenberger C, Schneider M, Heßling B, Stottmeier B, Wessbecher IM, Schirmacher P, McKeating JA, Protzer U, Durantel D, Lucifora J, Dejardin E, Heikenwalder M.
PMID: 33991110
Hepatology. 2021 Oct;74(4):1766-1781. doi: 10.1002/hep.31902. Epub 2021 Aug 15.

BACKGROUND AND AIMS: Therapeutic strategies against HBV focus, among others, on the activation of the immune system to enable the infected host to eliminate HBV. Hypoxia-inducible factor 1 alpha (HIF1α) stabilization has been associated with impaired immune responses. HBV...

Cite
Riedl T, Faure-Dupuy S, Rolland M, et al. Hypoxia-Inducible Factor 1 Alpha-Mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence. Hepatology. 2021;74(4):1766-1781doi: 10.1002/hep.31902.
Riedl, T., Faure-Dupuy, S., Rolland, M., Schuehle, S., Hizir, Z., Calderazzo, S., Zhuang, X., Wettengel, J., Lopez, M. A., Barnault, R., Mirakaj, V., Prokosch, S., Heide, D., Leuchtenberger, C., Schneider, M., Heßling, B., Stottmeier, B., Wessbecher, I. M., Schirmacher, P., McKeating, J. A., Protzer, U., Durantel, D., Lucifora, J., Dejardin, E., & Heikenwalder, M. (2021). Hypoxia-Inducible Factor 1 Alpha-Mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence. Hepatology (Baltimore, Md.), 74(4), 1766-1781. https://doi.org/10.1002/hep.31902
Riedl, Tobias, et al. "Hypoxia-Inducible Factor 1 Alpha-Mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence." Hepatology (Baltimore, Md.) vol. 74,4 (2021): 1766-1781. doi: https://doi.org/10.1002/hep.31902
Riedl T, Faure-Dupuy S, Rolland M, Schuehle S, Hizir Z, Calderazzo S, Zhuang X, Wettengel J, Lopez MA, Barnault R, Mirakaj V, Prokosch S, Heide D, Leuchtenberger C, Schneider M, Heßling B, Stottmeier B, Wessbecher IM, Schirmacher P, McKeating JA, Protzer U, Durantel D, Lucifora J, Dejardin E, Heikenwalder M. Hypoxia-Inducible Factor 1 Alpha-Mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence. Hepatology. 2021 Oct;74(4):1766-1781. doi: 10.1002/hep.31902. Epub 2021 Aug 15. PMID: 33991110; PMCID: PMC7611739.
Copy Download .nbib Format: NLM
The Influence of Liver L. casei Factor on Spontaneous Breast Cancer in Mice.

Science (New York, N.Y.)

Lewisohn R, Leuchtenberger C, Leucetenberger R, Keresztesy JC.
PMID: 17819687
Science. 1946 Nov 08;104(2706):436-7. doi: 10.1126/science.104.2706.436.

No abstract available.

Cite
Lewisohn R, Leuchtenberger C, Leucetenberger R, et al. The Influence of Liver L. casei Factor on Spontaneous Breast Cancer in Mice. Science. 1946;104(2706):436-7doi: 10.1126/science.104.2706.436.
Lewisohn, R., Leuchtenberger, C., Leucetenberger, R., & Keresztesy, J. C. (1946). The Influence of Liver L. casei Factor on Spontaneous Breast Cancer in Mice. Science (New York, N.Y.), 104(2706), 436-7. https://doi.org/10.1126/science.104.2706.436
Lewisohn, R, et al. "The Influence of Liver L. casei Factor on Spontaneous Breast Cancer in Mice." Science (New York, N.Y.) vol. 104,2706 (1946): 436-7. doi: https://doi.org/10.1126/science.104.2706.436
Lewisohn R, Leuchtenberger C, Leucetenberger R, Keresztesy JC. The Influence of Liver L. casei Factor on Spontaneous Breast Cancer in Mice. Science. 1946 Nov 08;104(2706):436-7. doi: 10.1126/science.104.2706.436. PMID: 17819687.
Copy Download .nbib Format: NLM
THE INFLUENCE OF "FOLIC ACID" ON SPONTANEOUS BREAST CANCERS IN MICE.

Science (New York, N.Y.)

Leuchtenberger R, Leuchtenberger C, Laszlo D, Lewisohn R.
PMID: 17758597
Science. 1945 Jan 12;101(2611):46. doi: 10.1126/science.101.2611.46.

Complete regressions of spontaneous breast cancers in mice were observed in 38 among 89 animals (43 per cent.). The treatment consisted of daily intravenous injections of 5 micrograms of l. casei factor ("folic acid"). The treated animals lived longer...

Cite
Leuchtenberger R, Leuchtenberger C, Laszlo D, et al. THE INFLUENCE OF "FOLIC ACID" ON SPONTANEOUS BREAST CANCERS IN MICE. Science. 1945;101(2611):46doi: 10.1126/science.101.2611.46.
Leuchtenberger, R., Leuchtenberger, C., Laszlo, D., & Lewisohn, R. (1945). THE INFLUENCE OF "FOLIC ACID" ON SPONTANEOUS BREAST CANCERS IN MICE. Science (New York, N.Y.), 101(2611), 46. https://doi.org/10.1126/science.101.2611.46
Leuchtenberger, R, et al. "THE INFLUENCE OF "FOLIC ACID" ON SPONTANEOUS BREAST CANCERS IN MICE." Science (New York, N.Y.) vol. 101,2611 (1945): 46. doi: https://doi.org/10.1126/science.101.2611.46
Leuchtenberger R, Leuchtenberger C, Laszlo D, Lewisohn R. THE INFLUENCE OF "FOLIC ACID" ON SPONTANEOUS BREAST CANCERS IN MICE. Science. 1945 Jan 12;101(2611):46. doi: 10.1126/science.101.2611.46. PMID: 17758597.
Copy Download .nbib Format: NLM
Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.

The open rheumatology journal

Feuchtenberger M, Müller S, Roll P, Waschbisch A, Schäfer A, Kneitz C, Wiendl H, Tony HP.
PMID: 19156222
Open Rheumatol J. 2008;2:81-8. doi: 10.2174/1874312900802010081. Epub 2008 Dec 03.

OBJECTIVES: Transient B cell depletion with the monoclonal anti-CD20 antibody rituximab has shown favourable clinical responses in patients with rheumatoid arthritis (RA). Recently a characteristic regeneration pattern of B cell subpopulations has been reported. However, little is known about...

Cite
Feuchtenberger M, Müller S, Roll P, et al. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheumatol J. 2008;2:81-8doi: 10.2174/1874312900802010081.
Feuchtenberger, M., Müller, S., Roll, P., Waschbisch, A., Schäfer, A., Kneitz, C., Wiendl, H., & Tony, H. P. (2008). Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. The open rheumatology journal, 281-8. https://doi.org/10.2174/1874312900802010081
Feuchtenberger, Martin, et al. "Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis." The open rheumatology journal vol. 2 (2008): 81-8. doi: https://doi.org/10.2174/1874312900802010081
Feuchtenberger M, Müller S, Roll P, Waschbisch A, Schäfer A, Kneitz C, Wiendl H, Tony HP. Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Open Rheumatol J. 2008;2:81-8. doi: 10.2174/1874312900802010081. Epub 2008 Dec 03. PMID: 19156222; PMCID: PMC2627533.
Copy Download .nbib Format: NLM
Hepatitis B Serology in Patients with Rheumatic Diseases.

The open rheumatology journal

Feuchtenberger M, Schäfer A, Philipp Nigg A, Rupert Kraus M.
PMID: 27708728
Open Rheumatol J. 2016 Aug 31;10:39-48. doi: 10.2174/1874312901610010039. eCollection 2016.

BACKGROUND: Only limited data are available on the prevalence of hepatitis B in patients with proven rheumatic diseases and thus the risk of reactivation under immunosuppressive therapy.OBJECTIVE: To analyse hepatitis B serology in patients with rheumatic diseases prior to...

Cite
Feuchtenberger M, Schäfer A, Philipp Nigg A, et al. Hepatitis B Serology in Patients with Rheumatic Diseases. Open Rheumatol J. 2016;10:39-48doi: 10.2174/1874312901610010039.
Feuchtenberger, M., Schäfer, A., Philipp Nigg, A., & Rupert Kraus, M. (2016). Hepatitis B Serology in Patients with Rheumatic Diseases. The open rheumatology journal, 1039-48. https://doi.org/10.2174/1874312901610010039
Feuchtenberger, Martin, et al. "Hepatitis B Serology in Patients with Rheumatic Diseases." The open rheumatology journal vol. 10 (2016): 39-48. doi: https://doi.org/10.2174/1874312901610010039
Feuchtenberger M, Schäfer A, Philipp Nigg A, Rupert Kraus M. Hepatitis B Serology in Patients with Rheumatic Diseases. Open Rheumatol J. 2016 Aug 31;10:39-48. doi: 10.2174/1874312901610010039. eCollection 2016. PMID: 27708728; PMCID: PMC5039958.
Copy Download .nbib Format: NLM
Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care.

Clinical and experimental rheumatology

Behrens F, Burmester GR, Feuchtenberger M, Kellner H, Kuehne C, Liebhaber A, Wassenberg S, Gerlach J, Zortel M, Hofmann MW, Amberger C.
PMID: 34001304
Clin Exp Rheumatol. 2021 May 14; Epub 2021 May 14.

OBJECTIVES: To assess whether tocilizumab treatment is associated with changes in depression symptoms in patients with rheumatoid arthritis (RA) during routine daily care.METHODS: We retrospectively analysed data from a German non-interventional study (ARATA) of adult, tocilizumab-naïve RA patients who...

Cite
Behrens F, Burmester GR, Feuchtenberger M, et al. Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care. Clin Exp Rheumatol. 2021;
Behrens, F., Burmester, G. R., Feuchtenberger, M., Kellner, H., Kuehne, C., Liebhaber, A., Wassenberg, S., Gerlach, J., Zortel, M., Hofmann, M. W., & Amberger, C. (2021). Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care. Clinical and experimental rheumatology, .
Behrens, Frank, et al. "Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care." Clinical and experimental rheumatology vol. (2021).
Behrens F, Burmester GR, Feuchtenberger M, Kellner H, Kuehne C, Liebhaber A, Wassenberg S, Gerlach J, Zortel M, Hofmann MW, Amberger C. Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care. Clin Exp Rheumatol. 2021 May 14; Epub 2021 May 14. PMID: 34001304.
Copy Download .nbib Format: NLM
Characterising a homozygous two-exon deletion in UQCRH: comparing human and mouse phenotypes.

EMBO molecular medicine

Vidali S, Gerlini R, Thompson K, Urquhart JE, Meisterknecht J, Aguilar-Pimentel JA, Amarie OV, Becker L, Breen C, Calzada-Wack J, Chhabra NF, Cho YL, da Silva-Buttkus P, Feichtinger RG, Gampe K, Garrett L, Hoefig KP, Hölter SM, Jameson E, Klein-Rodewald T, Leuchtenberger S, Marschall S, Mayer-Kuckuk P, Miller G, Oestereicher MA, Pfannes K, Rathkolb B, Rozman J, Sanders C, Spielmann N, Stoeger C, Szibor M, Treise I, Walter JH, Wurst W, Mayr JA, Fuchs H, Gärtner U, Wittig I, Taylor RW, Newman WG, Prokisch H, Gailus-Durner V, Hrabě de Angelis M.
PMID: 34750991
EMBO Mol Med. 2021 Dec 07;13(12):e14397. doi: 10.15252/emmm.202114397. Epub 2021 Nov 08.

Mitochondrial disorders are clinically and genetically diverse, with isolated complex III (CIII) deficiency being relatively rare. Here, we describe two affected cousins, presenting with recurrent episodes of severe lactic acidosis, hyperammonaemia, hypoglycaemia and encephalopathy. Genetic investigations in both cases...

Cite
Vidali S, Gerlini R, Thompson K, et al. Characterising a homozygous two-exon deletion in UQCRH: comparing human and mouse phenotypes. EMBO Mol Med. 2021;13(12):e14397doi: 10.15252/emmm.202114397.
Vidali, S., Gerlini, R., Thompson, K., Urquhart, J. E., Meisterknecht, J., Aguilar-Pimentel, J. A., Amarie, O. V., Becker, L., Breen, C., Calzada-Wack, J., Chhabra, N. F., Cho, Y. L., da Silva-Buttkus, P., Feichtinger, R. G., Gampe, K., Garrett, L., Hoefig, K. P., Hölter, S. M., Jameson, E., Klein-Rodewald, T., Leuchtenberger, S., Marschall, S., Mayer-Kuckuk, P., Miller, G., Oestereicher, M. A., Pfannes, K., Rathkolb, B., Rozman, J., Sanders, C., Spielmann, N., Stoeger, C., Szibor, M., Treise, I., Walter, J. H., Wurst, W., Mayr, J. A., Fuchs, H., Gärtner, U., Wittig, I., Taylor, R. W., Newman, W. G., Prokisch, H., Gailus-Durner, V., & Hrabě de Angelis, M. (2021). Characterising a homozygous two-exon deletion in UQCRH: comparing human and mouse phenotypes. EMBO molecular medicine, 13(12), e14397. https://doi.org/10.15252/emmm.202114397
Vidali, Silvia, et al. "Characterising a homozygous two-exon deletion in UQCRH: comparing human and mouse phenotypes." EMBO molecular medicine vol. 13,12 (2021): e14397. doi: https://doi.org/10.15252/emmm.202114397
Vidali S, Gerlini R, Thompson K, Urquhart JE, Meisterknecht J, Aguilar-Pimentel JA, Amarie OV, Becker L, Breen C, Calzada-Wack J, Chhabra NF, Cho YL, da Silva-Buttkus P, Feichtinger RG, Gampe K, Garrett L, Hoefig KP, Hölter SM, Jameson E, Klein-Rodewald T, Leuchtenberger S, Marschall S, Mayer-Kuckuk P, Miller G, Oestereicher MA, Pfannes K, Rathkolb B, Rozman J, Sanders C, Spielmann N, Stoeger C, Szibor M, Treise I, Walter JH, Wurst W, Mayr JA, Fuchs H, Gärtner U, Wittig I, Taylor RW, Newman WG, Prokisch H, Gailus-Durner V, Hrabě de Angelis M. Characterising a homozygous two-exon deletion in UQCRH: comparing human and mouse phenotypes. EMBO Mol Med. 2021 Dec 07;13(12):e14397. doi: 10.15252/emmm.202114397. Epub 2021 Nov 08. PMID: 34750991; PMCID: PMC8649870.
Copy Download .nbib Format: NLM
PREVENTION OF TUMOR GROWTH (CARCINOMA 2163) BY INTRAVENOUS INJECTIONS OF YEAST AND VITAMINS.

Science (New York, N.Y.)

Lewisohn R, Leuchtenberger C, Leuchtenberger R, Laszlo D, Bloch K.
PMID: 17812969
Science. 1941 Jul 18;94(2429):70-1. doi: 10.1126/science.94.2429.70.

No abstract available.

Cite
Lewisohn R, Leuchtenberger C, Leuchtenberger R, et al. PREVENTION OF TUMOR GROWTH (CARCINOMA 2163) BY INTRAVENOUS INJECTIONS OF YEAST AND VITAMINS. Science. 1941;94(2429):70-1doi: 10.1126/science.94.2429.70.
Lewisohn, R., Leuchtenberger, C., Leuchtenberger, R., Laszlo, D., & Bloch, K. (1941). PREVENTION OF TUMOR GROWTH (CARCINOMA 2163) BY INTRAVENOUS INJECTIONS OF YEAST AND VITAMINS. Science (New York, N.Y.), 94(2429), 70-1. https://doi.org/10.1126/science.94.2429.70
Lewisohn, R, et al. "PREVENTION OF TUMOR GROWTH (CARCINOMA 2163) BY INTRAVENOUS INJECTIONS OF YEAST AND VITAMINS." Science (New York, N.Y.) vol. 94,2429 (1941): 70-1. doi: https://doi.org/10.1126/science.94.2429.70
Lewisohn R, Leuchtenberger C, Leuchtenberger R, Laszlo D, Bloch K. PREVENTION OF TUMOR GROWTH (CARCINOMA 2163) BY INTRAVENOUS INJECTIONS OF YEAST AND VITAMINS. Science. 1941 Jul 18;94(2429):70-1. doi: 10.1126/science.94.2429.70. PMID: 17812969.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 27 entries